Dr. Jordi Llop is a radiochemist with strong background in the development of innovative strategies for the preparation of new radiotracers, and their application both at the clinical and pre-clinical levels using non-invasive molecular imaging techniques, always with a multi-modal approach and with a translational vision. Post-doctoral stays early in his career (Uppsala University PET Center and Clínica Universitaria de Navarra) and the industrial background at IAT-PRBB, where Dr. Llop was the Production Manager and Head of Radiochemistry of the Radiopharmaceutical lab, gave the opportunity to lead the production of PET tracers for clinical applications and participate in industry-sponsored clinical trials with big pharmaceutical companies. After moving to CICbiomaGUNE, Dr. Llop established his own research group, where in collaboration with national and international researchers, applies his background and experience in radiochemistry and molecular imaging to: (i) investigate biological and physiopathological aspects of diseases; (ii) develop novel diagnostic tools; and (iii) evaluate new drugs or treatments longitudinally in relevant animal models. Although the group is not disease-focussed and has shown activity in cardiovascular, respiratory and neurodegenerative diseases, one of the priority research activities of Dr. Llop is related to the development of therapeutic agents for application in oncology, and their evaluation in relevant animal models. In the last 5 years, Dr. Llop has published >50 scientific papers in peer-reviewed journals, several book chapters and have co-edited one book. Globally, the publishing record of Dr. llop produced around 1800 citations, and an H-index of 22. Within this last 5-year period, Dr. Llop has participated in national projects as Principal Investigator and as researcher in different EU initiatives in the FP7 and H2020 frame programs, all of them related to the use of PET imaging to the investigation of different pathologies at the preclinical level.